These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 28236776)

  • 1. Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.
    Jackisch C; Lammers P; Jacobs I
    Breast; 2017 Apr; 32():199-216. PubMed ID: 28236776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
    Paplomata E; Nahta R
    Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
    Whalen J
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating trastuzumab biosimilars and HER2-directed therapies into HER2-positive breast cancer management.
    Cuellar S
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S32-S40. PubMed ID: 32282173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
    Tesch ME; Gelmon KA
    Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
    Perez EA; Dang C; Lee C; Singh J; Wang K; Layton JB; Gilsenan A; Hackshaw MD; Cortes J
    Breast Cancer Res Treat; 2022 Jul; 194(1):1-11. PubMed ID: 35587323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of biosimilars in oncology, with a focus on trastuzumab.
    Nixon NA; Hannouf MB; Verma S
    Curr Oncol; 2018 Jun; 25(Suppl 1):S171-S179. PubMed ID: 29910660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union.
    Wyrwicz L; Rodríguez Sánchez CA; Sánchez-Rovira P; Lewis S; Sandschafer D; San T
    Future Oncol; 2024 Apr; 20(13):821-832. PubMed ID: 38305004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
    Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
    J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
    Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
    Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
    Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
    Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current challenges in HER2-positive breast cancer.
    Puglisi F; Fontanella C; Amoroso V; Bianchi GV; Bisagni G; Falci C; Fontana A; Generali D; Gianni L; Grassadonia A; Moscetti L; Portarena I; Rossi E; Marchetti P
    Crit Rev Oncol Hematol; 2016 Feb; 98():211-21. PubMed ID: 26638862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.
    Dzimitrowicz H; Berger M; Vargo C; Hood A; Abdelghany O; Raghavendra AS; Tripathy D; Valero V; Hatzis C; Pusztai L; Murthy R
    J Clin Oncol; 2016 Oct; 34(29):3511-3517. PubMed ID: 27298406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
    Blackwell K; Gligorov J; Jacobs I; Twelves C
    Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
    Hara F; Tajima K; Tanabe K
    Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
    Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
    BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars for breast cancer.
    Migliavacca Zucchetti B; Nicolò E; Curigliano G
    Expert Opin Biol Ther; 2019 Oct; 19(10):1015-1021. PubMed ID: 31248290
    [No Abstract]   [Full Text] [Related]  

  • 19. Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns.
    Resende HM; Ladislau L; Cardoso ACF; Brandão JDP; Assis BR; Cardoso P; Marassi PHA; Castilho V
    JCO Glob Oncol; 2021 Aug; 7():1316-1324. PubMed ID: 34415791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
    Hamilton EP; Kaklamani V; Falkson C; Vidal GA; Ward PJ; Patre M; Chui SY; Rotmensch J; Gupta K; Molinero L; Li Y; Emens LA
    Clin Breast Cancer; 2021 Dec; 21(6):539-551. PubMed ID: 34154926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.